{"id":143002,"date":"2023-02-28T09:25:01","date_gmt":"2023-02-28T14:25:01","guid":{"rendered":"https:\/\/44.250.171.167\/?p=143002"},"modified":"2023-02-28T09:25:03","modified_gmt":"2023-02-28T14:25:03","slug":"earnings-dr-lal-path-labs-ltd-nselalpathlab-q3fy23-results-out-total-income-fell-2-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-dr-lal-path-labs-ltd-nselalpathlab-q3fy23-results-out-total-income-fell-2-yoy\/","title":{"rendered":"Earnings | Dr Lal Path Labs Ltd (NSE:LALPATHLAB): Q3FY23 Results Out; Total Income fell 2% YoY"},"content":{"rendered":"\n

Dr Lal Path Labs Ltd (NSE:LALPATHLAB)<\/a> is a leading diagnostic services provider in India. The company was founded in 1949 by Dr. S.K. Lal and is currently headquartered in New Delhi, India. Dr Lal Path Labs operates a network of over 200 clinical laboratories, more than 2,600 patient service centers, and over 7,000 pickup points across India, Nepal, and Bangladesh. The company offers a wide range of diagnostic and related healthcare tests and services, including pathology, radiology, and cardiology tests. <\/p>\n\n\n\n

Dr. Lal Pathlabs Ltd, released its Q3FY23 financial results. The report shows that the company’s non-COVID revenue grew by 9.1% in Q3FY23, reaching Rs 478 crore compared to Rs 438 crore in Q3FY22. However, the total revenue declined by 1.5% in Q3FY23, reaching Rs 489 crore compared to Rs 497 crore in Q3FY22. The COVID and allied segment contributed only 2% to the revenue in Q3FY23, while it contributed 12% in Q3FY22.<\/p>\n\n\n\n

Dr. Lal Pathlabs’ normalized earnings before interest, taxes, depreciation, and amortization (EBITDA), adjusted for stock-based compensation and corporate social responsibility, was Rs 122 crore in Q3FY23, with a margin of 24.9%, compared to Rs 119 crore in the same quarter the previous year. Normalized profit before tax (PBT) was Rs 89 crore in Q3FY23, with a margin of 18.2%, compared to Rs 90 crore in the same quarter last year. The normalized profit after tax (PAT) was Rs 66 crore in Q3FY23, with a margin of 13.5%, which is the same as the previous year’s Q3. The company reported a consolidated profit after tax of Rs 54 crore, a 7% decline from the same quarter the previous year, where it reported a net profit of Rs 58 crore. The revenue for the December quarter also decreased to Rs 489 crore compared to Rs 497 crore in the previous year’s Q3.<\/p>\n\n\n\n

In conclusion, Dr. Lal Pathlabs’ Q3FY23 results showed that while the non-COVID revenue grew, the total revenue declined, and the company’s consolidated profit after tax decreased compared to the same period last year. However, the normalized EBITDA and PBT remained steady.<\/p>\n","protected":false},"excerpt":{"rendered":"

Dr Lal Path Labs Ltd (NSE:LALPATHLAB) is a leading diagnostic services provider in India. The company was founded in 1949 by Dr. S.K. Lal and is currently headquartered in New Delhi, India. Dr Lal Path Labs operates a network of over 200 clinical laboratories, more than 2,600 patient service centers, and over 7,000 pickup points […]<\/p>\n","protected":false},"author":1932,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[8665],"class_list":["post-143002","post","type-post","status-publish","format-standard","hentry","category-earnings","category-healthcare-stocks","tag-diagnostics"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":132319,"url":"https:\/\/alphastreet.com\/india\/earnings-infographic-dr-lal-pathlabs-q1-2023-revenue-and-profit-decline\/","url_meta":{"origin":143002,"position":0},"title":"Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline","author":"Manoj_Nair","date":"August 3, 2022","format":false,"excerpt":"Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for the first quarter of 2023. The company also announced an interim dividend of \u20b96 per share. First-quarter revenues dropped 17% year-over-year to \u20b9502.7 crores, hurt by a sharp\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":139887,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-limited-q3-fy23-net-profit-down-by-8\/","url_meta":{"origin":143002,"position":1},"title":"Dr. Lal PathLabs Limited Q3 FY23; Net Profit Down By 8%","author":"Hardik Bhandare","date":"February 2, 2023","format":false,"excerpt":"Dr. Lal PathLabs Limited (NSE: LALPATHLAB) reported a Revenue from Operations of \u20b9489.4 Crores, a decline of 1.5% from the previous year. The Consolidated Net Profit for the business also decreased by 8% year over year, to \u20b953.6 Crore from \u20b958.2 Crore. Earnings per Share is \u20b96.35 for this quarter.","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":132307,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-limited-research-report\/","url_meta":{"origin":143002,"position":2},"title":"Dr Lal PathLabs Limited Research Report","author":"sreerupa","date":"August 3, 2022","format":false,"excerpt":"Stock Data Ticker: LALPATHLAB Exchange :\u00a0\u00a0\u00a0\u00a0 NSE BSE:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 539524 Industry:\u00a0\u00a0\u00a0\u00a0\u00a0 Diagnostic Price Performance Last 7 days\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 8.70% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -38.28% Last 12 months\u00a0\u00a0\u00a0\u00a0 -39.34% The stock is showing a downward trend due to Tata 1mg's disruption expectations in the diagnostic business. It is expected that due to the intervention of Tata's\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":132298,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":143002,"position":3},"title":"Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 3, 2022","format":false,"excerpt":"https:\/\/youtu.be\/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly non-COVID revenue of INR482 crore, a growth of 25% YoYs. Additionally, COVID revenue significantly declined by 91% from INR221 crore to INR21 crore in 1Q23. Q&A Highlights: Pooja\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130921,"url":"https:\/\/alphastreet.com\/india\/research-summary-dr-lal-path-labs-limited-q4-fy-2022\/","url_meta":{"origin":143002,"position":4},"title":"Research Summary Dr Lal PathLabs Limited Q4 FY 2022","author":"sreerupa","date":"July 1, 2022","format":false,"excerpt":"Overview Dr Lal PathLabs Limited\u00a0is an Indian diagnostic company. It was incorporated in 1949. The headquarters is situated in Delhi, India. It has 70+ years of experience in diagnostics. It has successfully served 100 million patients in the last 5 years.\u00a0 It has 277 clinical labs, including the National Reference\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":129608,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":143002,"position":5},"title":"Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 18, 2022","format":false,"excerpt":"https:\/\/youtu.be\/XGfFd6kLFCE Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=143002"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143002\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=143002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=143002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=143002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}